Stocks of Codexis Inc. (NASDAQ:CDXS) traded higher last session on Wall Street, up 5.14% to $3.07.
According to the data, Codexis Inc. (NASDAQ:CDXS) has 8 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $6.00, we find $9.00. Given the previous closing price of $2.92, this indicates a potential upside of 208.22 percent. CDXS stock price is now 7.64% away from the 50-day moving average and -34.01% away from the 200-day moving average. The market capitalization of the company currently stands at $201.98M.
A total of 1 analysts have issued a hold rating and 7 have given it a buy rating. Brokers who have rated the stock have averaged $11.14 as their price target over the next twelve months.
In other news, NICOLS JOHN J, Director sold 35,714 shares of the company’s stock on Apr 18. The stock was sold for $147,874 at an average price of $4.14. Upon completion of the transaction, the Director now directly owns 783,965 shares in the company, valued at $2.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 17, Director NICOLS JOHN J sold 35,714 shares of the business’s stock. A total of $151,377 was realized by selling the stock at an average price of $4.24. This leaves the insider owning 783,965 shares of the company worth $2.41 million. Insiders disposed of 762,197 shares of company stock worth roughly $2.34 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CDXS stock. A new stake in Codexis Inc. shares was purchased by PARADIGM CAPITAL MANAGEMENT INC/NY during the first quarter worth $614,000. EMPIRE FINANCIAL MANAGEMENT COMPANY, LLC invested $261,000 in shares of CDXS during the first quarter. In the first quarter, ALPHACREST CAPITAL MANAGEMENT LLC acquired a new stake in Codexis Inc. valued at approximately $218,000. BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in CDXS for approximately $177,000. THRIVENT FINANCIAL FOR LUTHERANS purchased a new stake in CDXS valued at around $170,000 in the second quarter. In total, there are 231 active investors with 95.90% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $3.0000 for Codexis Inc. (NASDAQ: CDXS). During the past 12 months, Codexis Inc. has had a low of $2.18 and a high of $12.92. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.40, and a quick ratio of 3.30. The fifty day moving average price for CDXS is $2.8352 and a two-hundred day moving average price translates $4.6364 for the stock.
The latest earnings results from Codexis Inc. (NASDAQ: CDXS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.34, missing analysts’ expectations of -$0.31 by -0.03. This compares to -$0.13 EPS in the same period last year. The net profit margin was -41.20% and return on equity was -32.80% for CDXS. The company reported revenue of $12.98 million for the quarter, compared to $35.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -63.27 percent. For the current quarter, analysts expect CDXS to generate $18.09M in revenue.
Codexis Inc.(CDXS) Company Profile
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company’s platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
